CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues	[1]	$ 12,028	$ 13,118
Costs and expenses:
Cost of sales	[1],[2]	2,378	2,433
Selling, informational and administrative expenses	[1],[2]	2,873	3,339
Research and development expenses	[1],[2]	1,724	1,703
Amortization of intangible assets	[1]	885	1,183
Restructuring charges and certain acquisition-related costs	[1]	69	46
(Gain) on completion of Consumer Healthcare JV transaction	[1]	(6)	0
Other (income)/deductions––net	[1]	221	92
Income from continuing operations before provision for taxes on income	[1],[3]	3,885	4,323
Provision for taxes on income	[1]	475	433
Income from continuing operations	[1]	3,410	3,889
Discontinued operations––net of tax	[1]	0	0
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	3,410	3,889
Less: Net income attributable to noncontrolling interests	[1]	9	6
Net income attributable to Pfizer Inc.	[1]	$ 3,401	$ 3,884
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.61	$ 0.69
Discontinued operations––net of tax (in dollars per share)	[1]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.61	0.69
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.61	0.68
Discontinued operations––net of tax (in dollars per share)	[1]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.61	$ 0.68
Weighted-average shares––basic	[1]	5,545	5,635
Weighted-average shares––diluted	[1]	5,613	5,750

[1] Amounts may not add due to rounding.

[2] Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

[3] Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4.

[4] Amounts may not add due to rounding.

[5] Amounts may not add due to rounding.

[6] Amounts may not add due to rounding.